4 % may not sound like much, but the price premium that Novo Nordisk won for its long-acting basal insulin Tresiba compared with Sanofi’s Lantus is quite significant, as it has been won on the Japanese market.
“On the surface of it 4 % does not sound like much, but it is not half bad for Novo Nordisk. You should keep in mind that it is the fourth basal insulin approved in Japan, and it is difficult to win price premiums in Japan. To me, this price premium is very good. In fact, only 3 out of 43 approved drugs in 2012 achieved a higher price than comparable drugs. Tresiba is among those three,” says Sydbank-analyst Søren Løntoft Hansen.